In order to understand if there is other unknown side effect during the clinical trail, the PMS (Post-Marketing Study) will be conducted to learn more treatment experiences on patients, and collect their information for further study.
No. 9 of IRPMA COP Benchmarks regulates that all PMS shall go through JIRB, IRB or Ethics Committee and must be registered on the website of IRPMA PMS registry system. It is to ensure the studies conducted on patients have been approved by JIRB, IRB and protect patient’s right of privacy. The public can also get the information and objective of the PMS through the registry system.

Company Name	Title of Study	Update Date
Daiichi Sankyo Taiwan	Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice in Patients with Venous Thromboembolism in Korea and Taiwan	2020-12-25
Pfizer Inc.	Health-related quality life and health utility among Taiwanese women with advanced/metastatic breast cancer	2020-12-25
Novartis (Taiwan) Co., Ltd	Registry of Ruxolitinib Treatment in Patients with Intermediate-2 or High Risk of Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), or Post-essential Thrombocythemia Myelofibrosis (PET-MF)	2020-12-25
Novartis (Taiwan) Co., Ltd	A non-interventional, prospective 12-months study to characterize the REAL-life effectiveness and treatment pattern of Secukinumab and current standard of care in patient with chronic plaque psoriasis eligible for systemic treatment in the Asia-Pacific and Middle East regions (REALIA)	2018-09-18
Bayer Taiwan Co., Ltd.	EXPERT, EXPosurE Registry RiociguaT in patients with pulmonary hypertension	2018-09-18
Bayer Taiwan Co., Ltd.	OPTIMIS - Outcomes of HCC patients treated with TACE followed or not followed by sorafenib and the influence of timing to initiate sorafenib	2018-09-18
Bayer Taiwan Co., Ltd.	RIFTOS - Radioactive Iodine reFractory asymptomatic patients in differentiated Thyroid cancer – an Observational Study to assess the use of MultiKinase Inhibitors	2017-01-26
Bayer Taiwan Co., Ltd.	Xarelto Evidence in Real Life of Patients Preference and Satisfaction Study (X-PRESS)	2017-01-26
Johnson & Johnson Pte Ltd	A multicenter, prospective, longitudinal registry of patients with prostate cancer in Asia	2017-01-26
Astellas Pharma Taiwan, Inc.	GLOBAL MULTICENTRE KIDNEY TRANSPLANT ADVAGRAFTM CONVERSION REGISTRY. A NON-INTERVENTIONAL POST-AUTHORISATION STUDY (PAS)	2017-01-26